Collectively, our in vitro data provide strong evidence for both STAT3 inhibition and dual STAT3/IGF-1R inhibition in STAT3-high and -low GBM cells, respectively, and synergize with TMZ, thus suggesting the advancement of both therapeutic approaches in a clinical setting. The gene discussed is STAT3; the disease is glioblastoma.